XXXX : a multidisciplinary approach.

@entity5 @entity1 @entity1442 @entity1211
In this paper, we briefly review the relation between @entity5 and @entity1211 ( @entity1211 ), an association that has been recognized for more than a century. In particular we focus on @entity1211 as predictor and prognostic factor for @entity5 and the antineoplastic potential of antithrombotic treatment. @entity5 may cause disturbances in the haemostatic system by numerous mechanisms that can lead to an increased risk of @entity1211 . @entity1 with known @entity5 are at increased risk of @entity1211 ; however, @entity1211 may also be a predictor of subsequent @entity5 in the years afterwards. Furthermore, @entity5 @entity1 with @entity1211 are more likely to have @entity1442 and a worse prognosis than @entity5 @entity1 without a @entity1211 episode. These findings may have implications for the clinical care of @entity1 with @entity1211 in terms of screening for @entity5 . However, extensive @entity5 screening programs are not recommended in general for @entity1 with @entity1211 . A wide range of antithrombotic drugs including heparin, oral anticoagulants, and platelet inhibitors have been examined in order to study the effect on the prevention and treatment of various @entity5 . These efforts have resulted in a considerable amount of useful data from animal models and a number of promising reports from retrospective analyses and small-scale trials linking antithrombotic treatment with an increased survival in @entity5 @entity1 and even a lower risk of primary @entity5 . However, the clinical implications of these findings must await properly designed and conducted randomized clinical trials.
